sibo and glp 1 ACG 2025 Annual Meeting Posters Targeting GLP-1, GIP & GCG
Description
Moderate intensity is generally well-tolerated
Increased competition typically drives innovation and can pressure prices down, but effects depend on market dynamics and payer responses
doi: 10.3389/fmed.2025.1612034 Received 15 April 2025 Accepted 24 October 2025 Published 21 November 2025 Volume 12 - 2025 Edited by Cassiano Felippe Gonalves-de-Albuquerque, Rio de Janeiro State Federal University, Brazil Reviewed by Tamer A
Nationally in the U.S., an average of 1 percent of all patients have taken GLP-1 drugs in the past year
No exceptions
Clinical, Cosmetic and Investigational Dermatology
